Clinical trial
The Safety, Tolerability and Preliminary Efficacy of PD-L1 Monoclonal Antibody Combined With Lenalidomide in Third-line Post-Treatment of Patients With Microsatellite Stable Advanced Colorectal Cancer: A Phase I Clinical Study
NCT04326296 is registered in ClinicalTrials.gov with LiNing as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Safety, Tolerability and Preliminary Efficacy of PD-L1 Monoclonal Antibody Combined With Lenalidomide in Third-line Post-Treatment of Patients With Microsatellite Stable Advanced Colorectal Cancer: A Phase I Clinical Study
- Lead sponsor
- LiNing
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- May 30, 2020
- Completion date
- March 31, 2023
- Enrollment
- 33 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.